Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

ABSTRACT BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of vascular endothelial

growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumours. METHODS: In all, 49 patients received axitinib

5 mg twice daily (b.i.d.) with paclitaxel/carboplatin or gemcitabine/cisplatin in 3-week cycles. Following determination of the maximum tolerated dose, a squamous cell NSCLC expansion cohort

was enroled and received axitinib 5 mg b.i.d. with paclitaxel/carboplatin. RESULTS: Two patients experienced dose-limiting toxicities: febrile neutropenia (_n_=1) in the

paclitaxel/carboplatin cohort and fatigue (_n_=1) in the gemcitabine/cisplatin cohort. Common nonhaematologic treatment-related adverse events were hypertension (36.7%), diarrhoea (34.7%)

and fatigue (28.6%). No grade⩾3 haemoptysis occurred among 12 patients with squamous cell NSCLC. The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin

(_n_=27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (_n_=21). Pharmacokinetics of axitinib and chemotherapeutic agents were similar when administered alone or in

combination. CONCLUSION: Axitinib 5 mg b.i.d. may be combined with standard paclitaxel/carboplatin or gemcitabine/cisplatin regimens without evidence of overt drug–drug interactions. Both

combinations demonstrated clinical efficacy and were well tolerated. SIMILAR CONTENT BEING VIEWED BY OTHERS CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN NON-SMALL CELL LUNG

CANCER: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND PHASE 3 TRIAL Article Open access 25 August 2022 GEFITINIB (AN EGFR TYROSINE KINASE INHIBITOR) PLUS ANLOTINIB (AN MULTIKINASE INHIBITOR) FOR

UNTREATED, _EGFR-_MUTATED, ADVANCED NON-SMALL CELL LUNG CANCER (FL-ALTER): A MULTICENTER PHASE III TRIAL Article Open access 13 August 2024 SINTILIMAB WITH TWO CYCLES OF CHEMOTHERAPY FOR THE

TREATMENT OF ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER: A PHASE 2 CLINICAL TRIAL Article Open access 19 February 2024 MAIN New therapeutic strategies are needed to improve the efficacy

of chemotherapy regimens for advanced solid tumours. For patients with advanced non-small cell lung cancer (NSCLC), platinum-based doublets remain a standard of care (Stinchcombe and

Socinski, 2009). However, these treatments result in only modest improvements in survival (Burris, 2009). Addition of targeted agents, which act on specific signalling pathways involved in

tumour progression, to chemotherapy regimens may improve clinical outcomes. The vascular endothelial growth factor (VEGF) pathway has a key role in tumour-related angiogenesis, and its

deregulation is characteristic of many solid tumours (Brown et al, 1993; Ikeda et al, 1999; Berns et al, 2003; Saad et al, 2004; Keedy and Sandler, 2007). Novel agents have been developed to

target the VEGF ligand or its receptor. In several phase III studies, inhibition of VEGF signalling by the anti-VEGF antibody bevacizumab in combination with chemotherapy improved patient

outcomes compared with chemotherapy alone (Hurwitz et al, 2004; Sandler et al, 2006; Miller et al, 2007; Reck et al, 2010). In patients with advanced non-squamous NSCLC, bevacizumab

prolonged overall survival (OS) when combined with paclitaxel and carboplatin compared with chemotherapy alone (median OS, 12.3 _vs_ 10.3 months) (Sandler et al, 2006), and prolonged

progression-free survival, but not OS, when combined with gemcitabine and cisplatin (Reck et al, 2010). Investigation of antiangiogenic agents with different mechanisms of action, such as

tyrosine kinase inhibition, in combination with chemotherapy is warranted. Results from a phase III study showed that adding sorafenib, an inhibitor of multiple tyrosine kinases, to

carboplatin/paclitaxel did not prolong OS compared with chemotherapy alone in patients with NSCLC (Scagliotti et al, 2010). Nevertheless, other tyrosine kinase inhibitors that selectively

inhibit VEGF receptors may still offer clinical benefit when added to chemotherapy. Axitinib is an oral, potent and selective second-generation tyrosine kinase inhibitor of VEGF receptors 1,

2 and 3 (Hu-Lowe et al, 2008). When combined with docetaxel, carboplatin or gemcitabine in human tumour models, axitinib enhanced the antitumour efficacy of these agents (Hu-Lowe et al,

2008). In phase II studies of several tumour types, axitinib showed single-agent activity and was well tolerated (Rixe et al, 2007; Cohen et al, 2008; Rini et al, 2009; Schiller et al,

2009). In a phase II study of patients with advanced NSCLC receiving single-agent axitinib, median OS was 14.8 months (Schiller et al, 2009), which compares favourably with chemotherapy

(Burris, 2009). These data suggest axitinib may enhance the efficacy of standard chemotherapy regimens for the treatment of selected solid tumours, including NSCLC. Here, we report safety,

efficacy and pharmacokinetic findings from a phase I study of combination treatment with axitinib plus paclitaxel/carboplatin or gemcitabine/cisplatin in patients with advanced solid

tumours, including squamous cell NSCLC. PATIENTS AND METHODS STUDY DESIGN AND END POINTS This was a phase I, open-label, multicentre, dose-finding study consisting of nine treatment cohorts,

plus an expansion cohort of patients with squamous cell NSCLC who were enroled after determination of the maximum tolerated dose (MTD) of axitinib plus paclitaxel/carboplatin. Here, we

report findings from cohorts that received axitinib in combination with either paclitaxel/carboplatin (cohorts 1, 2 and 3 plus expansion) or gemcitabine/cisplatin. Findings from other

treatment cohorts are presented in an accompanying article (Martin et al, 2012). Primary end point was MTD of axitinib combined with either paclitaxel/carboplatin or gemcitabine/cisplatin.

Secondary end points included safety, tumour response rates and plasma pharmacokinetic profiles. This study was performed in accordance with the study protocol approved at each participating

centre, International Conference on Harmonisation Guidelines on Good Clinical Practice and applicable local regulatory requirements and laws. All patients provided written informed consent.

This trial is registered on ClinicalTrials.gov (NCT00454649). PATIENTS Patients aged ⩾18 years with any histologically or cytologically proven advanced solid malignancy suitable for

treatment with paclitaxel/carboplatin or gemcitabine/cisplatin were eligible. Inclusion criteria for all cohorts included an Eastern Cooperative Oncology Group performance status (ECOG PS)

of 0 or 1; no pre-existing uncontrolled hypertension (antihypertensive medications were permitted); adequate organ function; and no prior chemotherapy with platinum salts or taxanes for

metastatic disease except as noted below; adjuvant treatment with platinum salts or taxanes must have been completed ⩾12 months before enrolment. For patients receiving

gemcitabine/cisplatin, any type of previous chemotherapy was allowed and, for patients in the expansion cohort, any type of previous treatment was allowed. Patients with NSCLC with squamous

cell histology, or mixed histology that was predominantly squamous, were eligible for the expansion cohort, which received axitinib plus paclitaxel/carboplatin. Exclusion criteria included

myocardial infarction, congestive heart failure, cerebrovascular accident (including transient ischaemic attack) or pulmonary embolus <12 months before enrolment; haemoptysis (>0.5

teaspoon blood per day) within 1 week of enrolment; and at least one lung lesion with cavitation or any lesion invading and/or supporting large blood vessels. STUDY TREATMENTS Treatment

schedules are shown in Figure 1. All patients received axitinib twice daily (b.i.d.) with food. _In vitro_ studies indicate axitinib noncompetitively inhibits the cytochrome P450 (CYP) 2C8

enzyme (unpublished data) involved in paclitaxel metabolism (Monsarrat et al, 1993; Steed and Sawyer, 2007). Owing to potential for drug–drug interactions between axitinib and paclitaxel,

the axitinib lead-in dose was administered at 1, 3 and 5 mg b.i.d. for sequential cohorts 1, 2 and 3, respectively, started 3–5 days before the first dose of chemotherapy and continued for 2

days after the first chemotherapy dose. Cohorts 1, 2 and 3 were to enrol three to six patients, depending on the number of patients that experienced a dose-limiting toxicity (DLT) during

the first cycle (Table 1). If none of the first three patients experienced a DLT during the first cycle, the lead-in dose of axitinib was escalated in the subsequent cohort. If one of the

three patients experienced a DLT during the first cycle, the cohort was expanded to include a total of six patients, and if one of six patients experienced a DLT during the first cycle, the

lead-in dose of axitinib was escalated in the next cohort. The lead-in dose of axitinib for the gemcitabine/cisplatin cohort was 5 mg b.i.d. After the lead-in period, axitinib 5 mg b.i.d.

was administered continuously in all cohorts. Axitinib was interrupted 3 days before cycle 2 day 1 of chemotherapy administration and dosing was resumed on cycle 2 day 3; for cohorts 1 and

2, starting with cycle 2, axitinib was interrupted 1 day before chemotherapy infusion (day 21) and resumed on day 3 of each subsequent cycle. For the expansion cohort, axitinib was

administered at the MTD defined in cohorts 1–3, beginning cycle 1 day 1. All patients continued treatment with axitinib until disease progression or unacceptable toxicity. After cycle 1,

patients with no grade >2 adverse events (AEs) related to axitinib for consecutive 2-week periods could have their axitinib dose titrated to 7 mg b.i.d. and then to a maximum of 10 mg

b.i.d., unless BP measured >150/100 mm Hg or the patient was receiving antihypertensive medication. The axitinib dose was reduced to 3 mg b.i.d., and then to 2 mg b.i.d. in patients with

grade ⩾3 nonhaematologic treatment-related AEs. For patients who developed systolic BP >150 mm Hg or diastolic BP >100 mm Hg, new or additional antihypertensive therapy was started or

the dose of existing medication increased. If patients developed haemoptysis (>0.5 teaspoon of bright red blood per day), axitinib was discontinued and a radiologic assessment was to be

considered. For patients in the squamous cell NSCLC expansion cohort who developed cavitation after enrolment, axitinib was withheld and patients were assessed on a case-by-case basis.

Patients who permanently discontinued axitinib because of toxicity could continue to receive chemotherapy as long as treatment was considered clinically beneficial. Patients in cohorts 1–3

and the expansion cohort received paclitaxel (200 mg m–2; 3-h infusion) followed by carboplatin (area under the plasma concentration–time curve (AUC) target of 6 mg min ml−1; 30-min

infusion) every 3 weeks. Patients in the gemcitabine/cisplatin cohort received cisplatin (80 mg m−2 on day 1) and gemcitabine (1250 mg m−2 on days 1 and 8; 30-min infusion), followed by a

1-week rest period, in 3-week cycles. Chemotherapy regimens were modified on an individual basis according to patient tolerability at the discretion of the investigator.

Paclitaxel/carboplatin was delayed in patients with absolute granulocyte counts <1500 cells mm−3or platelet counts <100 000 cells mm−3 and discontinued if recovery did not occur after

4 weeks. Paclitaxel/carboplatin was withheld in patients with grade ⩾3 haematologic or nonhaematologic toxicities and resumed at one lower dose level when the toxicity was grade ⩽1.

Paclitaxel was reduced in patients with grade 2 neurotoxicity or withheld until neurotoxicity was grade ⩽1. The gemcitabine/cisplatin dose was reduced to 75% in patients with febrile

neutropenia, grade 4 neutropenia for ⩾7 days, grade 4 thrombocytopenia, bleeding grade>2 with grade 3 thrombocytopenia or grade 3 nonhaematologic toxicities during the prior cycle. The

gemcitabine/cisplatin dose was reduced to 50% or delayed in patients with grade 4 nonhaematologic toxicities during the prior cycle. Gemcitabine/cisplatin was delayed by 1 week if the

absolute neutrophil count was <1.0 × 109 l−1 and/or the platelet count was <100 × 109 l−1. If on day 8, the absolute neutrophil count was <1.0 × 109 l−1 and/or the platelet count

was <100 × 109 l−1, gemcitabine was not administered. Cisplatin was discontinued in patients with grade ⩾2 peripheral neurotoxicity, tinnitus or hearing loss during the prior cycle.

Prophylactic use of colony-stimulating factors was permitted in patients who experienced infection or grade 4 neutropenia during the previous cycle. Patients who discontinued chemotherapy

because of toxicity or because they completed the maximum number of cycles according to institutional practice could continue to receive axitinib as a single agent. ASSESSMENTS The MTD for

axitinib plus paclitaxel/carboplatin or gemcitabine/cisplatin was defined as the dose level at which no more than one of the first six patients enroled in each cohort experienced a DLT

during the first cycle of therapy, with two or more of the six patients experiencing a DLT at the next highest dose level. If the MTD was not exceeded within the planned dose levels, MTD was

defined as the maximum dose tested. Dose-limiting toxicities were defined as grade 4 neutropenia or thrombocytopenia for ⩾14 days, or grade 4 febrile neutropenia; proteinuria ⩾2 g/24 h;

haemoptysis (⩾ 0.5 teaspoon per day) for ⩾7 days; uncontrolled grade ⩾3 nonhaematologic toxicity for ⩾7 days; or inability to resume study treatment within 14 days after stopping because of

axitinib-related toxicity. Safety was monitored throughout the study, and AE severity was graded according to the Common Terminology Criteria for Adverse Events, version 3.0 (Trotti et al,

2003). Physical examinations, assessment of ECOG PS, chest X-rays and laboratory tests were conducted at baseline, day 1 of each cycle and at follow-up (28 days after the last dose).

Additional physical examinations and haematology tests were performed at days 8 and 15 of each cycle. For the squamous cell NSCLC expansion cohort, chest X-rays were performed to assess

tumour cavitation on even-numbered cycles when other tumour assessments were not performed. BP was monitored at each clinic visit, and patients were issued a home BP monitoring device and

diary and asked to record their BP at least twice daily before each axitinib dose. Patients were instructed to contact their physicians for systolic BP>150 mm Hg or diastolic BP>100 mm

 Hg. Home BP measurements were not used for DLT assessments. Tumours were radiologically assessed every two cycles, according to Response Evaluation Criteria in Solid Tumours (RECIST version

1.0) (Therasse et al, 2000). PHARMACOKINETIC ANALYSIS The pharmacokinetics of steady-state axitinib alone and chemotherapy alone, as well as the combination of steady-state axitinib plus

chemotherapy, were evaluated in each patient in all cohorts except the expansion cohort. Pharmacokinetics of steady-state axitinib when administered alone were determined using blood samples

collected pre-dose and 1, 2, 3, 4, 6 and 8 h after dosing on cycle 1 day –1. Pharmacokinetics of chemotherapy when administered alone were determined using blood samples collected on cycle

2 day 1. Pharmacokinetics of the combination of steady-state axitinib and chemotherapy were determined using blood samples collected on cycle 1 day 1. Samples for paclitaxel/carboplatin

analysis were collected pre-dose and 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24 and 30 h after the start of paclitaxel infusion. Samples for gemcitabine analysis were collected pre-dose and 0.25,

0.5, 0.75, 1, 1.25, 1.5, 2, 3 and 4 h after the start of infusion in tubes containing tetrahydrouridine, which prevented continued metabolism of gemcitabine during the processing of samples.

Samples for cisplatin analysis were collected pre-dose and 0.5, 1, 1.5, 2.5, 3.5, 5.5 and 7.5 h after the start of infusion. Plasma concentrations of axitinib were measured using a

validated high-performance liquid chromatography with tandem mass spectrometric detection method (LC/MS/MS) (Charles River Discovery and Development Services; Shrewsbury, MA, USA) (Rugo et

al, 2005). Concentrations of paclitaxel, gemcitabine and the gemcitabine metabolite 2′,2′-difluorodeoxyuridine (dFdU) in sodium heparin plasma were measured using a validated LC/MS/MS assay

(Covance Bioanalytical Services; Indianapolis, IN, USA) with ranges of 10–2000 ng ml–1, 50–50 000 ng ml–1 and 500–50 000 ng ml–1 for paclitaxel, gemcitabine and dFdU, respectively.

Concentrations of platinum from carboplatin and cisplatin in sodium heparin plasma and plasma ultrafiltrate (PUF) were measured using a validated inductively coupled plasma-MS assay (Covance

Laboratories; Madison, WI, USA) with ranges of 2.0–1000 ng ml–1and 1.0–500 ng ml–1 in plasma and PUF, respectively. All pharmacokinetic analyses were conducted using WinNonlin Professional

(version 4.01, Pharsight Corp.; Mountain View, CA, USA). STATISTICAL ANALYSIS All patients receiving at least one dose of study medication were included in the safety analysis. Patients

having one or more target lesion according to RECIST and a baseline assessment of disease and who received at least one dose of study medication were included in the analysis of best

objective response. Data were summarised using means, medians, s.d. and ranges for continuous data and frequencies and percentages for categorical data. RESULTS PATIENT DEMOGRAPHICS AND

DISPOSITION In all, 49 patients were enroled, including 28 patients in the paclitaxel/carboplatin cohorts and 21 patients in the gemcitabine/cisplatin cohort (Table 2). The most common

tumour type was NSCLC in 17 patients (34.7%), all of whom were in the paclitaxel/carboplatin cohorts. Study treatment duration for individual patients is shown in Figure 2. Patients received

axitinib for a median of 174 days (range 10–656) and 89 days (range 5–992) in the paclitaxel/carboplatin and gemcitabine/cisplatin cohorts, respectively. The median daily axitinib dose was

9.8 mg (range 4.7–15.1) in patients receiving paclitaxel/carboplatin and 9.0 mg (range 6.0–10.0) in patients receiving gemcitabine/cisplatin. Dosing of axitinib was reduced in 16 patients

(35.7% and 28.6% of patients in the paclitaxel/carboplatin and gemcitabine/cisplatin cohorts, respectively) and was interrupted in 24 patients (35.7% and 66.7% of patients in the

paclitaxel/carboplatin and gemcitabine/cisplatin cohorts, respectively). Median number of paclitaxel/carboplatin cycles was 6, 5 and 4 (range 1–6) for cohorts 1, 2 and 3, respectively;

median number of chemotherapy cycles was 4 (range 1–29) and 3 (range 1–9) for gemcitabine and cisplatin, respectively. A total of 26 patients receiving axitinib plus paclitaxel/carboplatin

discontinued the study, including 14 patients because of insufficient clinical response, 4 patients because of AEs and 8 patients for other reasons. In the gemcitabine/cisplatin cohort, 20

patients discontinued, including 10 because of insufficient clinical response, 6 because of AEs and 4 for other reasons. DLTS AND MTD One of the first six patients in cohort 3 receiving

axitinib/paclitaxel/carboplatin experienced a DLT of febrile neutropenia during the first cycle (Table 1), and the MTD was determined to be axitinib 5 mg b.i.d. continuously in combination

with paclitaxel 200 mg m–2 and carboplatin (AUC 6 mg min ml–1). One of the first six patients receiving axitinib/gemcitabine/cisplatin experienced a DLT of fatigue during the first cycle;

the MTD was determined to be axitinib 5 mg b.i.d. continuously in combination with cisplatin 80 mg m–2 (day 1) and gemcitabine 1250 mg m–2 (days 1 and 8). Dose titration to 10 mg b.i.d. was

achieved in three patients receiving paclitaxel/carboplatin. SAFETY AND TOLERABILITY Six patients discontinued the study because of treatment-related AEs, which were fatigue, cerebrovascular

accident and haemoptysis (_n_=1 each) in the paclitaxel/carboplatin cohorts and hypertension (_n_=2) and cerebrovascular accident (_n_=1) in the gemcitabine/cisplatin cohort. Common

treatment-related nonhaematologic AEs were hypertension (_n_=18; 36.7%), diarrhoea (_n_=17; 34.7%) and fatigue (_n_=14; 28.6%) (Table 3). Common grade ⩾3 treatment-related nonhaematologic

AEs across both treatment arms were fatigue (_n_=5; 10.2%) and hypertension (_n_=5; 10.2%). In addition to the patient in cohort 3 receiving axitinib/paclitaxel/carboplatin who had a DLT of

febrile neutropenia during the first cycle, one patient in cohort 2 experienced grade 4 febrile neutropenia; chemotherapy was reduced in this patient. In the paclitaxel/carboplatin cohorts,

two patients (7.1%) developed treatment-related stomatitis; both cases were classified as grade 2. No cases of grade⩾3 haemoptysis or grade 5 treatment-related AEs were reported.

Haematologic laboratory abnormalities occurred in most patients (Table 3). With the exceptions of lymphopenia in the gemcitabine/cisplatin cohort and neutropenia in both cohorts, the

majority of abnormalities were grade ⩽2. Grade 3/4 treatment-related abnormalities reported as AEs were thrombocytopenia (_n_=4; 8.2%), neutropenia (_n_=2; 4.1%) and anaemia and leukopenia

(_n_=1 each; 2.0%). CLINICAL ACTIVITY Of the evaluable patients, 15 (31.3%) achieved an objective response (Table 4), including 3 complete responses (6.3%). An additional 16 patients (33.3%)

had stable disease for >8 weeks. Objective responses were observed in patients with NSCLC (_n_=5), ovarian cancer (_n_=3), melanoma (_n_=2) and other tumour types (_n_=5).

PHARMACOKINETIC RESULTS Plasma pharmacokinetic parameters (maximum plasma concentration, AUC, clearance and volume of distribution) for paclitaxel, carboplatin, gemcitabine and its

metabolite dFdU and cisplatin were similar in the absence or presence of axitinib (Table 5; Figure 3). Axitinib pharmacokinetic parameters were similar in the absence or presence of

co-administered paclitaxel/carboplatin or gemcitabine/cisplatin (Table 5; Figure 3). DISCUSSION Combination treatment with chemotherapy and an agent targeting the VEGF pathway has been shown

to improve clinical outcome for several tumour types compared with chemotherapy alone (Hurwitz et al, 2004; Sandler et al, 2006; Miller et al, 2007; Reck et al, 2010). In this study,

axitinib combined with paclitaxel/carboplatin or gemcitabine/cisplatin was well tolerated and demonstrated clinical efficacy without any overt pharmacokinetic interactions for various

advanced solid tumours. The MTD for axitinib in combination with paclitaxel/carboplatin or gemcitabine/cisplatin was 5 mg b.i.d.; however, further dose escalation of axitinib was achieved in

some patients tolerating 5 mg b.i.d. Most AEs reported in this study were of mild-to-moderate grade, and the most common treatment-related nonhaematologic, grade ⩾3 AEs (hypertension,

diarrhoea and fatigue) were anticipated, based on results from prior phase II studies of axitinib (Rixe et al, 2007; Cohen et al, 2008; Spano et al, 2008; Rini et al, 2009; Schiller et al,

2009). Unlike DLTs observed with other VEGF receptor tyrosine kinase inhibitors, for example, sorafenib, where skin toxicities such as rash and hand–foot syndrome were predominant (Moore et

al, 2005; Strumberg et al, 2005), DLTs associated with axitinib in combination with paclitaxel/carboplatin or gemcitabine/cisplatin were febrile neutropenia and fatigue. Potential

overlapping toxicities between axitinib and the chemotherapeutic agents, such as fatigue, nausea, diarrhoea and stomatitis, did not appear to be appreciably exacerbated. Patients receiving

anti-VEGF therapies have an increased risk of developing hypertension (Jain and Townsend, 2007; Zhu et al, 2007; Wu et al, 2008), and the incidence of hypertension in this study was

consistent with previous axitinib trials (Rixe et al, 2007; Cohen et al, 2008; Rini et al, 2009; Schiller et al, 2009). Moreover, grade ⩾3 hypertension reported here was comparable to that

reported in phase III studies in various advanced solid tumours treated with the VEGF inhibitor bevacizumab plus chemotherapy (4–14.8%) (Sandler et al, 2006; Miller et al, 2007; Saltz et al,

2008). These data favour the use of antihypertensive medication and suggest the possible need for axitinib dose adjustments in patients who develop hypertension while receiving axitinib

plus chemotherapy. Of note, no cases of grade ⩾3 haemoptysis were reported in this study, although mild haemoptysis was reported in one patient who received axitinib plus

paclitaxel/carboplatin. Bevacizumab is contraindicated in patients with squamous cell NSCLC because of the incidence of severe or fatal pulmonary haemorrhage (2004); thus, patients with

squamous cell NSCLC were excluded from the phase III study evaluating bevacizumab combined with paclitaxel and carboplatin for NSCLC (Sandler et al, 2006). In this study, additional

eligibility requirements, for example, exclusion of patients who had blood vessels with possible tumour involvement, may have mitigated, in part, the potential risk of haemoptysis. It will

require further investigation in a larger study to confirm whether axitinib plus chemotherapy may be safely administered to patients with squamous cell NSCLC. A phase II trial (NCT00735904)

evaluating axitinib combined with gemcitabine/cisplatin for squamous cell NSCLC was recently completed. Data reported here suggest the ability to administer paclitaxel/carboplatin or

gemcitabine/cisplatin with axitinib without altering pharmacokinetics of these agents. Axitinib metabolism is primarily mediated by CYP3A4 and to a lesser extent by CYP1A2, CYP2C19 and

UDP-glucuronosyltransferase 1A1 as determined from _in vitro_ studies with human liver microsomes (unpublished data). _In vitro_ studies indicate that axitinib competitively inhibits CYP1A2

and non-competitively inhibits CYP2C8 with inhibitor constants of 0.7 _μ_ M (0.27 _μ_g ml–1) and 0.5 _μ_ M (0.19 _μ_g ml–1), respectively (unpublished data). Since paclitaxel is an

established CYP2C8 substrate (Monsarrat et al, 1993; Steed and Sawyer, 2007) and axitinib inhibits CYP2C8 _in vitro_, increases in plasma concentrations of paclitaxel when administered in

combination with axitinib were possible. Thus, patients were administered escalating lead-in doses of axitinib (starting at 1 mg b.i.d.) in sequential cohorts in combination with

paclitaxel/carboplatin. Similar paclitaxel pharmacokinetics in the absence and presence of axitinib indicate that at clinically relevant plasma concentrations of axitinib, significant

clinical CYP2C8 inhibition does not occur. In addition, there were no clinically apparent exacerbations of known paclitaxel toxicities. Similarly, no overt changes in pharmacokinetics were

observed between axitinib and cisplatin, carboplatin or gemcitabine and its metabolite dFdU, although interactions were not anticipated since axitinib is metabolised via pathways that are

distinct from these agents. Both carboplatin and cisplatin are eliminated by glomerular filtration (Duffull and Robinson, 1997; Yao et al, 2007). Gemcitabine (2′,2′-difluorodeoxycytidine) is

sequentially phosphorylated intracellularly by deoxycytidine kinase and converted to di- and triphosphate products. Observed plasma concentrations of axitinib in combination with either

paclitaxel/carboplatin or gemcitabine/cisplatin were consistent with those reported in other phase I studies of axitinib as monotherapy or in combination with chemotherapy (Rugo et al, 2005;

Sharma et al, 2010). Plasma exposures observed in this study of paclitaxel, carboplatin (PUF), cisplatin (PUF) and gemcitabine when administered alone were similar to those previously

reported in the literature (Villalona-Calero et al, 2004; Kobayashi et al, 2007; Ricart et al, 2008; Okamoto et al, 2010). Combinations of bevacizumab with chemotherapy have shown promising

results in phase III studies of different tumour types; however, randomised trials of tyrosine kinase inhibitors targeting VEGF receptors in combination with chemotherapy have not shown a

benefit for these combinations. Although the efficacy data for axitinib in combination with chemotherapy reported here are encouraging, they are exploratory, as would be expected from any

phase I trial. The number of patients in each cohort was small, making it difficult to draw any definitive conclusions about the utility of axitinib combined with paclitaxel/carboplatin or

gemcitabine/cisplatin in these patient populations. Nevertheless, they offer direction for ongoing and future clinical studies with sufficient statistical power for comprehensive analysis of

the safety and efficacy of these combinations for the treatment of various cancers. In conclusion, axitinib at a starting dose of 5 mg b.i.d. may be combined with paclitaxel/carboplatin or

gemcitabine/cisplatin at standard doses, with no apparent overlapping toxicities and no overt changes in plasma pharmacokinetic parameters. Both combinations showed antitumour activity in

patients with advanced solid tumours, including squamous cell NSCLC. Phase II studies of axitinib in combination with paclitaxel/carboplatin, gemcitabine/cisplatin and pemetrexed/cisplatin

for NSCLC were recently completed. CHANGE HISTORY * _ 04 OCTOBER 2012 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at

publication _ REFERENCES * Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC,

Foekens JA (2003) Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. _Clin Cancer

Res_ 9: 1253–1258 CAS  PubMed  Google Scholar  * Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993) Increased expression of vascular permeability factor

(vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. _Am J Pathol_ 143: 1255–1262 CAS  PubMed  PubMed Central  Google Scholar  * Burris HA (2009)

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. _Oncogene_ 28 (Suppl 1): S4–S13 Article  CAS  Google Scholar  * Cohen EE, Rosen LS, Vokes EE, Kies MS,

Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced

thyroid cancer: results from a phase II study. _J Clin Oncol_ 26: 4708–4713 Article  CAS  Google Scholar  * Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of

carboplatin. _Clin Pharmacokinet_ 33: 161–183 Article  CAS  Google Scholar  * Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY,

McTigue MA, Murray BW, Kania RS, O’Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective

inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. _Clin Cancer Res_ 14: 7272–7283 Article  CAS  Google Scholar  * Hurwitz H, Fehrenbacher L, Novotny W,

Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and

leucovorin for metastatic colorectal cancer. _N Engl J Med_ 350: 2335–2342 Article  CAS  Google Scholar  * Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y,

Kanehiro H, Hisanaga M, Nakano H, Miyake M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. _Br J Cancer_ 79: 1553–1563 Article  CAS  Google Scholar  * Jain M,

Townsend RR (2007) Chemotherapy agents and hypertension: a focus on angiogenesis blockade. _Curr Hypertens Rep_ 9: 320–328 Article  CAS  Google Scholar  * Keedy VL, Sandler AB (2007)

Inhibition of angiogenesis in the treatment of non-small cell lung cancer. _Cancer Sci_ 98: 1825–1830 Article  CAS  Google Scholar  * Kobayashi M, Oba K, Sakamoto J, Kondo K, Nagata N,

Okabayashi T, Namikawa T, Hanazaki K (2007) Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. _Gastric Cancer_

10: 52–57 Article  CAS  Google Scholar  * Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB (2012) Phase

I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. _Br J Cancer_ doi:10.1038/bjc.2012.407; e-pub ahead of print Article  CAS 

Google Scholar  * Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic

breast cancer. _N Engl J Med_ 357: 2666–2676 Article  CAS  Google Scholar  * Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC, Rowinsky EK (1993)

Hepatic metabolism and biliary excretion of Taxol in rats and humans. _J Natl Cancer Inst Monogr_ 39–46 * Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz

B (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with

advanced, refractory solid tumors. _Ann Oncol_ 16: 1688–1694 Article  CAS  Google Scholar  * Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M,

Fukino K, Tanigawa T, Nakagawa K (2010) Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung

cancer. _Invest New Drugs_ 28: 844–853 Article  CAS  Google Scholar  * Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C

(2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial

(AVAiL). _Ann Oncol_ 21: 1804–1809 Article  CAS  Google Scholar  * Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW,

Rowinsky EK, Rothenberg ML (2008) Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with

solid tumors. _Clin Cancer Res_ 14: 7947–7955 Article  CAS  Google Scholar  * Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase

II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. _J Clin Oncol_ 27: 4462–4468 Article  CAS  Google Scholar  * Rixe O, Bukowski RM, Michaelson MD, Wilding G,

Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II

study. _Lancet Oncol_ 8: 975–984 Article  Google Scholar  * Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of

the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. _J Clin Oncol_ 23: 5474–5483 Article  CAS  Google Scholar  * Saad RS,

Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. _Mod Pathol_ 17: 197–203

Article  CAS  Google Scholar  * Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab

in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. _J Clin Oncol_ 26: 2013–2019 Article  CAS  Google

Scholar  * Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. _N

Engl J Med_ 355: 2542–2550 Article  CAS  Google Scholar  * Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O,

Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced

non-small-cell lung cancer. _J Clin Oncol_ 28: 1835–1842 Article  CAS  Google Scholar  * Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ,

von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. _J Clin Oncol_ 27: 3836–3841 Article  Google Scholar

  * Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL (2010) A phase I study of axitinib (AG-013736) in combination with

bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. _Ann Oncol_ 21: 297–304 Article  CAS  Google Scholar  * Spano JP,

Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O (2008) Efficacy of gemcitabine plus axitinib

compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. _Lancet_ 371: 2101–2108 Article  CAS  Google Scholar  * Steed H, Sawyer

MB (2007) Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. _Pharmacogenomics_ 8: 803–815 Article  CAS  Google Scholar  * Stinchcombe TE, Socinski MA (2009) Current

treatments for advanced stage non-small cell lung cancer. _Proc Am Thorac Soc_ 6: 233–241 Article  CAS  Google Scholar  * Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M,

Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular

endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. _J Clin Oncol_ 23: 965–972 Article  CAS  Google Scholar  * The Medical Letter

Online (2004) Two new drugs for colon cancer. _Med Lett Drugs Ther_ 46: 46–48 Google Scholar  * Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van

Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer,

National Cancer Institute of the United States, National Cancer Institute of Canada. _J Natl Cancer Inst_ 92: 205–216 Article  CAS  Google Scholar  * Trotti A, Colevas AD, Setser A, Rusch

V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

_Semin Radiat Oncol_ 13: 176–181 Article  Google Scholar  * Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M,

Valdivieso M, Geary R, Oliver JW, Holmlund J (2004) A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in

patients with advanced non-small cell lung cancer. _Clin Cancer Res_ 10: 6086–6093 Article  CAS  Google Scholar  * Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of

hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. _Lancet Oncol_ 9: 117–123 Article  CAS  Google Scholar  * Yao X, Panichpisal K, Kurtzman N, Nugent

K (2007) Cisplatin nephrotoxicity: a review. _Am J Med Sci_ 334: 115–124 Article  Google Scholar  * Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with

bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. _Am J Kidney Dis_ 49: 186–193 Article  CAS  Google Scholar  Download references

ACKNOWLEDGEMENTS This study was sponsored by Pfizer Inc. Support was provided in part by National Institutes of Health grant P30 CA006927 to the Fox Chase Cancer Center. We thank the

patients who participated in this study and the physicians who referred them, as well as the study coordinators and data managers, Shelley Mayfield and Carol Martins at Pfizer Inc. for

support of the study conduct, and Gamal ElSawah, Pfizer Medical Affairs, for his review of the manuscript. Medical writing support was provided by Joanna Bloom, of UBC Scientific Solutions

(Southport, CT, USA) and Christine Arris at ACUMED (Tytherington, UK) and was funded by Pfizer Inc. AUTHOR INFORMATION Author notes * A J Olszanski Present address: Current address:

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, AUTHORS AND AFFILIATIONS * Section of Oncology/Hematology, Ingalls Hospital, Harvey, IL, USA M F Kozloff *

Department of Medicine, University of Chicago, Chicago, IL, USA M F Kozloff * Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA L P Martin & R B Cohen * The

Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland M Krzakowski * Department of Medical Oncology, Georgia Health Sciences University Cancer Center, Augusta, GA, USA T A Samuel *

Clinical Research Department, Columbia Basin Hematology and Oncology, Kennewick, WA, USA T A Rado * Medical Oncology Department, Hospital del Mar, Barcelona, Spain E Arriola * University

Hospital La Paz, Madrid, Spain J De Castro Carpeño * Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA R S Herbst * Pfizer Oncology, San

Diego, CA, USA J Tarazi, S Kim, B Rosbrook, M Tortorici & A J Olszanski Authors * M F Kozloff View author publications You can also search for this author inPubMed Google Scholar * L P

Martin View author publications You can also search for this author inPubMed Google Scholar * M Krzakowski View author publications You can also search for this author inPubMed Google

Scholar * T A Samuel View author publications You can also search for this author inPubMed Google Scholar * T A Rado View author publications You can also search for this author inPubMed 

Google Scholar * E Arriola View author publications You can also search for this author inPubMed Google Scholar * J De Castro Carpeño View author publications You can also search for this

author inPubMed Google Scholar * R S Herbst View author publications You can also search for this author inPubMed Google Scholar * J Tarazi View author publications You can also search for

this author inPubMed Google Scholar * S Kim View author publications You can also search for this author inPubMed Google Scholar * B Rosbrook View author publications You can also search for

this author inPubMed Google Scholar * M Tortorici View author publications You can also search for this author inPubMed Google Scholar * A J Olszanski View author publications You can also

search for this author inPubMed Google Scholar * R B Cohen View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to M F

Kozloff. ADDITIONAL INFORMATION This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will

switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. RIGHTS AND PERMISSIONS From twelve months after its original publication, this work is licensed under

the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kozloff, M., Martin, L., Krzakowski, M. _et al._ Phase I trial of axitinib combined with platinum doublets in patients with advanced

non-small cell lung cancer and other solid tumours. _Br J Cancer_ 107, 1277–1285 (2012). https://doi.org/10.1038/bjc.2012.406 Download citation * Received: 24 February 2012 * Revised: 30

July 2012 * Accepted: 15 August 2012 * Published: 18 September 2012 * Issue Date: 09 October 2012 * DOI: https://doi.org/10.1038/bjc.2012.406 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative KEYWORDS * axitinib * chemotherapy * pharmacokinetics * solid tumours * non-small cell lung cancer